Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EQUILIBRIX-S: VMX-C001 vs Usual Care in Patients on FXa DOAC Requiring Urgent Surgery
NCT07288489Phase 3Recruiting
- Sponsor
- VarmX
- Start
- Aug 2026
- Primary completion
- Jan 2029
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 18
01
Overview
A Phase 3 trial of reltodecacog alfa in coagulation disorder, sponsored by VarmX. Started Aug 2026; status: recruiting.
02
Drugs
reltodecacog alfa
03
Conditions
coagulation disorder
Beyond the preview
Go deeper on NCT07288489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07288489.